文献速递血脂与心血管预防冠心病

PCSK9基因变异对冠心病与缺血性卒中风险的不同影响

Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.
PubMed 文献 · Eur Heart J · 2018-01-01

结果发现rs11591147 T等位基因与LDL-C降低0.5 mmol/L及冠心病风险降低23%相关,但与缺血性卒中风险无显著关联;其他PCSK9变异也显示对缺血卒中的影响弱于冠心病。结论提示PCSK9基因变异与缺血性卒中的关联显著弱于冠心病,而随机试验中PCSK9抑制剂对两者的相对风险降低相似,这对孟德尔随机化预测治疗效应的可靠性具有启示。

要点

  • PCSK9功能缺失变异rs11591147与LDL-C降低及冠心病风险降低相关。
  • 该变异与缺血性卒中及其亚型风险无显著关联。
  • 其他PCSK9变异对缺血卒中的影响也弱于冠心病。

核心结论

  • PCSK9基因变异与缺血性卒中的关联显著弱于冠心病,而随机试验中PCSK9抑制剂对两者的相对风险降低相似。

主要发现

  • rs11591147 T等位基因与LDL-C水平降低0.5 mmol/L相关(P = 9 × 10-143)。
  • rs11591147 T等位基因与冠心病风险降低23%相关(OR: 0.77, 95% CI: 0.69-0.87, P = 7 × 10-6)。
  • rs11591147 T等位基因与缺血性卒中风险无显著关联(OR: 1.04, 95% CI: 0.84-1.28, P = 0.74),与缺血性卒中亚型也无显著关联。
  • 其他PCSK9变异的信息也一致显示对缺血性卒中的影响弱于冠心病。

临床怎么用

  • PCSK9基因变异与缺血性卒中的关联弱于冠心病,提示孟德尔随机化预测治疗效应时需谨慎。
  • 随机试验中PCSK9抑制剂对缺血性卒中和冠心病的相对风险降低相似,支持其临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: PCSK9 genetic variants that have large effects on low-density lipoprotein cholesterol (LDL-C) and coronary heart disease (CHD) have prompted the development of therapeutic PCSK9-inhibition. However, there is limited evidence that PCSK9 variants are associated with ischaemic stroke (IS). METHODS AND RESULTS: Associations of the loss-of-function PCSK9 genetic variant (rs11591147; R46L), and five additional PCSK9 variants, with IS and IS subtypes (cardioembolic, large vessel, and small vessel) were estimated in a meta-analysis involving 10 307 IS cases and 19 326 controls of European ancestry. They were then compared with the associations of these variants with LDL-C levels (in up to 172 970 individuals) and CHD (in up to 60 801 CHD cases and 123 504 controls). The rs11591147 T allele was associated with 0.5 mmol/L lower LDL-C level (P = 9 × 10-143) and 23% lower CHD risk [odds ratio (OR): 0.77, 95% confidence interval (CI): 0.69-0.87, P = 7 × 10-6]. However, it was not associated with risk of IS (OR: 1.04, 95% CI: 0.84-1.28, P = 0.74) or IS subtypes. Information from additional PCSK9 variants also indicated consistently weaker effects on IS than on CHD. CONCLUSION: PCSK9 genetic variants that confer life-long lower PCSK9 and LDL-C levels appear to have significantly weaker, if any, associations with risk of IS than with risk of CHD. By contrast, similar proportional reductions in risks of IS and CHD have been observed in randomized trials of therapeutic PCSK9-inhibition. These findings have implications for our understanding of when Mendelian randomization can be relied upon to predict the effects of therapeutic interventions.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Hopewell JC, Malik R, Valdés-Márquez E, et al. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. Eur Heart J. 2018. PMID: 29020353. doi:10.1093/eurheartj/ehx373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。